SCHEMBL25612974

SCHEMBL25612974

Cc1cc(C(C)(C)C)nc2c1OCCN2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RET P07949 7/20 0.35
UHRF1 Q96T88 1/20 0.32
HTR1A P08908 2/20 0.31
HTR1D P28221 2/20 0.31
HTR1B P28222 2/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
CHRM2 P08172 1/20 0.31
ADRA2A P08913 1/20 0.31
CYP2D6 P10635 1/20 0.31
CHRM1 P11229 1/20 0.31
DRD2 P14416 1/20 0.31
TSHR P16473 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
CHRM3 P20309 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20416986 0.80 UHRF1 (0.50) MAPTALDH1A1GAAHSD17B10RET
SCHEMBL1812071 0.78 ALDH1A1 (0.33) MAPTALDH1A1GAAHSD17B10RET
SCHEMBL25612973 0.75 MAPT (0.35) MAPTALDH1A1GAAHSD17B10HTR1A
SCHEMBL25612969 0.73
SCHEMBL21400681 0.71 ALDH1A1 (0.44) MAPTALDH1A1GAAHSD17B10RET
SCHEMBL24568395 0.70 CCR1 (0.43) RETADRA1ACYP3A4
SCHEMBL12807110 0.70 KCNH2 (0.34) KCNH2
SCHEMBL25612960 0.69 MAPT (0.41) MAPTALDH1A1GAAHSD17B10RET
SCHEMBL22693042 0.69 ALDH1A1 (0.41) MAPTALDH1A1GAAHSD17B10ADRA2A
SCHEMBL21187103 0.68 RET (0.40) MAPTALDH1A1GAAHSD17B10RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 MAPT 2208/4885ALDH1A1 3019/4885GAA 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.